Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort
In this real-world cohort, we observed a wide variety of different treatment sequences applied in daily clinical practice, some of which were in discordance with the current guidelines. Fear that patients may never get around to treatment with CDK4/6i if a patient did not start with a CDK4/6i was not supported by our study results.
Authors
- Alwin D. R. Huitema (ORCID: https://orcid.org/0000-0003-1939-4639)
- Lishi Lin
- Vincent O. Dezentjé (ORCID: https://orcid.org/0000-0001-7650-8407)
- Cornelia AM Almekinders
- Gabe S. Sonke
- Jos H. Beijnen
Institutions
- Utrecht University (NL)
- The Netherlands Cancer Institute (NL)
- University Medical Center Utrecht (NL)
- Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NL)
- Princess Máxima Center (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2024-11-07
- DOI
- https://doi.org/10.1007/s10549-024-07542-0
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.42